Effectiveness of Intraductal Meibomian Gland Probing in Addition to the Conventional Treatment in Patients with Obstructive Meibomian Gland Dysfunction

İncekalan, Tuğba Kurumoğlu; Harbiyeli, İbrahim İnan; Yaǵmur, Meltem; Erdem, Elif

doi:10.1080/09273948.2018.1522357

Cited by 14 publications

(48 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beyond antibiotics and CsA, various office-based procedures have been evaluated in the treatment of MGD including intense pulse light, thermopulsation treatments (Lipiflow) and meibomian gland probing. [77][78][79] Each of these approaches are supported by studies that show improvement in symptoms and signs of disease, but more solid randomised control studies or studies that use patients who are resistant to ATs are limited with respect to these newer modalities. However, if ATs are not adequate, some patients with MGD may benefit from treatment escalation, such as antibiotics, anti-inflammatories and office-based procedures.…”

Section: Meibomian Gland Dysfunctionmentioning

confidence: 99%

Dry eye: why artificial tears are not always the answer

et al. 2021

View full text Add to dashboard Cite

Dry eye disease (DED) is a multifactorial disease that manifests in patients with a variety of symptoms and signs such as ocular pain, visual issues, rapid tear evaporation and/or decreased tear production. It is a global health problem and is the leading cause of optometry and ophthalmology clinic visits. The mainstay therapy for DED is artificial tears (ATs), which mimics tears and improves tear stability and properties. ATs have been found to improve symptoms and signs of disease in all DED subtypes, including aqueous deficient DED and evaporative DED. However, given the heterogeneity of DED, it is not surprising that ATs are not effective in all patients. When AT fails to relieve symptoms and/or signs of DED, it is critical to identify the underlying contributors to disease and escalate therapy appropriately. This includes underlying systemic diseases, meibomian gland dysfunction, anatomical abnormalities and neuropathic dysfunction. Thus, this review will discuss the benefits and limitations of ATs and review conditions when escalation of therapy should be considered in DED.

show abstract

Section: Meibomian Gland Dysfunctionmentioning

confidence: 99%

Dry eye: why artificial tears are not always the answer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Four out of the 14 reviewed papers were published in 2019 alone. 13,14,23,30 Additionally, one review article looking at MGP was published this same year. 24 MGP is also mentioned in recent reviews looking at the treatment of MGD, with one published as recently as January, 2020.…”

Section: 1mentioning

confidence: 99%

“…22,23,25,26,36 Four of these five were conducted by the same first author using his past patients' charts. 22,23,25,26 Nine of the included articles described prospective studies, 10,13,14,16,21,29,30,34,38 four of which were RCTs. 13,14,16,21 A majority of the included studies had no control group.…”

Section: 1mentioning

confidence: 99%

Intraductal meibomian gland probing and its efficacy in the treatment of meibomian gland dysfunction

Magno

Moschowits

Arita

et al. 2021

Survey of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…57 Other studies have demonstrated the safety and efficacy of probing for patients with obstructive MGD. [58][59][60] Moreover, probing was associated with an increase in meibomian gland area 61 as determined by non-invasive meibography. 62 Of note, neither subjects nor investigators were masked to treatment allocation in the studies of intraductal probing performed to date ( Table 2), indicating that caution should be exercised in drawing conclusions from their findings.…”

Section: Intraductal Probingmentioning

confidence: 99%

“…A randomised, controlled study of 25 patients with obstructive MGD showed that both signs and symptoms were improved one month after probing 2016. Other studies have demonstrated the safety and efficacy of probing for patients with obstructive MGD 2019. Moreover, probing was associated with an increase in meibomian gland area2018 as determined by non‐invasive meibography 2013…”

Section: Treatment Modalitiesmentioning

confidence: 99%

Non‐pharmaceutical treatment options for meibomian gland dysfunction

Arita

Fukuoka

2020

Clinical and Experimental Optometry

View full text Add to dashboard Cite

This review examines currently available non-pharmaceutical treatment modalities for meibomian gland dysfunction. A detailed search of the PubMed and MEDLINE databases was performed to identify original articles in English that have evaluated such nonpharmaceutical therapies in patients with this condition. Conventional therapies such as application of a warming compress, the practice of lid hygiene, and manual expression of meibomian glands as well as more technologically advanced approaches such as intraductal probing, thermal pulsation, and intense pulsed light therapy are included in the review. These non-pharmaceutical treatment options may each have a role to play in the management of meibomian gland dysfunction, but more studies are necessary to compare treatments directly under identical experimental conditions in order to determine their relative efficacy. Additional large-scale, randomised, controlled trials are also required to provide more information such as the specific indications best suited to each treatment modality, the efficacy of such approaches in combination with pharmaceutical-based therapy, and the mechanisms of action of some of the more technologically advanced systems.

show abstract

Effectiveness of Intraductal Meibomian Gland Probing in Addition to the Conventional Treatment in Patients with Obstructive Meibomian Gland Dysfunction

Cited by 14 publications

References 21 publications

Dry eye: why artificial tears are not always the answer

Dry eye: why artificial tears are not always the answer

Intraductal meibomian gland probing and its efficacy in the treatment of meibomian gland dysfunction

Non‐pharmaceutical treatment options for meibomian gland dysfunction

Contact Info

Product

Resources

About